Terumo Joins Two U.S.-based Venture Capital Funds Committing Investment up to USD 50 Million, to Support Medtech Startups

August 29, 2019

TOKYO, JAPAN - August 29, 2019 - Terumo Corporation (TSE: 4543), a leading global medical device manufacturer, today announced that it will invest in two U.S.-based venture capital funds, Strategic Healthcare Investment Partners (S.H.I.P) with offices in Silicon Valley, California, and Dublin, Ireland, and Catalyst Health Ventures (CHV) with offices in Boston, Massachusetts. Terumo will invest USD 25 million in each fund, in total USD 50 million.

Venture investing in the medtech field can complement internal R&D with new technology, expanded strategy, and also further complement business development and acquisition. In that light, Terumo has utilized this strategy previously, as a Limited Partner of Emergent Medical Partners (EMP) since 2013, including having a Terumo liaison work with the fund. Terumo has reviewed more than 2,000 startups over the last 6 years based on its network built through this relationship. While investing in the fund, Terumo also directly invested in multiple startups. These activities contribute to Terumo's internal capabilities, giving access to new technology collaborations and acquisitions that fits its business strategy.

Now, Terumo will expand this activity with presence on the U.S. West Coast and East Coast, including having a liaison in both funds. This enables Terumo to be involved in more geographically and technically diversified deals. The Company's breadth of relationships will be enhanced from early to late stage technologies, aiming to deliver solutions for large unmet medical needs.

About Terumo Corporation

Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers, with approximately US$6 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices, including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician-office use. Terumo contributes to society by providing valued products and services to the healthcare market, and by responding to the needs of healthcare providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.

Media Contact

Corporate Communication Dept., Terumo Corporation

(Notice) Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.